178 related articles for article (PubMed ID: 31450235)
1. Prediction of significant prostate cancer in biopsy-naïve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS.
Radtke JP; Giganti F; Wiesenfarth M; Stabile A; Marenco J; Orczyk C; Kasivisvanathan V; Nyarangi-Dix JN; Schütz V; Dieffenbacher S; Görtz M; Stenzinger A; Roth W; Freeman A; Punwani S; Bonekamp D; Schlemmer HP; Hohenfellner M; Emberton M; Moore CM
PLoS One; 2019; 14(8):e0221350. PubMed ID: 31450235
[TBL] [Abstract][Full Text] [Related]
2. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
3. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
[TBL] [Abstract][Full Text] [Related]
4. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort.
Gayet M; Mannaerts CK; Nieboer D; Beerlage HP; Wijkstra H; Mulders PFA; Roobol MJ
Eur Urol Focus; 2018 Mar; 4(2):228-234. PubMed ID: 28753781
[TBL] [Abstract][Full Text] [Related]
5. Comparing the prediction of prostate biopsy outcome using the Chinese Prostate Cancer Consortium (CPCC) Risk Calculator and the Asian adapted Rotterdam European Randomized Study of Screening for Prostate Cancer (ERSPC) Risk Calculator in Chinese and European men.
Chen R; Verbeek JFM; Yang Y; Song Z; Sun Y; Roobol MJ
World J Urol; 2021 Jan; 39(1):73-80. PubMed ID: 32279141
[TBL] [Abstract][Full Text] [Related]
6. A comparison of prostate cancer prediction models in men undergoing both magnetic resonance imaging and transperineal biopsy: Are the models still relevant?
Doan P; Graham P; Lahoud J; Remmers S; Roobol MJ; Kim L; Patel MI
BJU Int; 2021 Dec; 128 Suppl 3():36-44. PubMed ID: 34374190
[TBL] [Abstract][Full Text] [Related]
7. External validation of novel magnetic resonance imaging-based models for prostate cancer prediction.
Püllen L; Radtke JP; Wiesenfarth M; Roobol MJ; Verbeek JFM; Wetter A; Guberina N; Pandey A; Hüttenbrink C; Tschirdewahn S; Pahernik S; Hadaschik BA; Distler FA
BJU Int; 2020 Mar; 125(3):407-416. PubMed ID: 31758738
[TBL] [Abstract][Full Text] [Related]
8. Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer.
Deniffel D; Healy GM; Dong X; Ghai S; Salinas-Miranda E; Fleshner N; Hamilton R; Kulkarni G; Toi A; van der Kwast T; Zlotta A; Finelli A; Perlis N; Haider MA
Radiology; 2021 Aug; 300(2):369-379. PubMed ID: 34032510
[TBL] [Abstract][Full Text] [Related]
9. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
10. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
Brown LC; Ahmed HU; Faria R; El-Shater Bosaily A; Gabe R; Kaplan RS; Parmar M; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham A; Oldroyd R; Parker C; Bott S; Burns-Cox N; Dudderidge T; Ghei M; Henderson A; Persad R; Rosario DJ; Shergill I; Winkler M; Soares M; Spackman E; Sculpher M; Emberton M
Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065
[TBL] [Abstract][Full Text] [Related]
11. Avoiding Unnecessary Magnetic Resonance Imaging (MRI) and Biopsies: Negative and Positive Predictive Value of MRI According to Prostate-specific Antigen Density, 4Kscore and Risk Calculators.
Falagario UG; Martini A; Wajswol E; Treacy PJ; Ratnani P; Jambor I; Anastos H; Lewis S; Haines K; Cormio L; Carrieri G; Rastinehad AR; Wiklund P; Tewari A
Eur Urol Oncol; 2020 Oct; 3(5):700-704. PubMed ID: 31548130
[TBL] [Abstract][Full Text] [Related]
12. A prostate biopsy risk calculator based on MRI: development and comparison of the Prospective Loyola University multiparametric MRI (PLUM) and Prostate Biopsy Collaborative Group (PBCG) risk calculators.
Patel HD; Koehne EL; Shea SM; Fang AM; Gerena M; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Rais-Bahrami S; Gupta GN
BJU Int; 2023 Feb; 131(2):227-235. PubMed ID: 35733400
[TBL] [Abstract][Full Text] [Related]
13. A predictive model based on biparametric magnetic resonance imaging and clinical parameters for improved risk assessment and selection of biopsy-naïve men for prostate biopsies.
Boesen L; Thomsen FB; Nørgaard N; Løgager V; Balslev I; Bisbjerg R; Thomsen HS; Jakobsen H
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):609-616. PubMed ID: 30988407
[TBL] [Abstract][Full Text] [Related]
14. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
[TBL] [Abstract][Full Text] [Related]
15. External Validation and Comparison of Prostate Cancer Risk Calculators Incorporating Multiparametric Magnetic Resonance Imaging for Prediction of Clinically Significant Prostate Cancer.
Saba K; Wettstein MS; Lieger L; Hötker AM; Donati OF; Moch H; Ankerst DP; Poyet C; Sulser T; Eberli D; Mortezavi A
J Urol; 2020 Apr; 203(4):719-726. PubMed ID: 31651228
[TBL] [Abstract][Full Text] [Related]
16. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
[TBL] [Abstract][Full Text] [Related]
17. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.
Roobol MJ; van Vugt HA; Loeb S; Zhu X; Bul M; Bangma CH; van Leenders AG; Steyerberg EW; Schröder FH
Eur Urol; 2012 Mar; 61(3):577-83. PubMed ID: 22104592
[TBL] [Abstract][Full Text] [Related]
18. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
19. Adaptation and external validation of the European randomised study of screening for prostate cancer risk calculator for the Chinese population.
Chiu PK; Roobol MJ; Nieboer D; Teoh JY; Yuen SK; Hou SM; Yiu MK; Ng CF
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):99-104. PubMed ID: 27897172
[TBL] [Abstract][Full Text] [Related]
20. External validation of two MRI-based risk calculators in prostate cancer diagnosis.
Petersmann AL; Remmers S; Klein T; Manava P; Huettenbrink C; Pahernik SA; Distler FA
World J Urol; 2021 Nov; 39(11):4109-4116. PubMed ID: 34169337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
